Recombinant Human VEGF Receptors binding domains Compared For Fourier Protein

Catalog No.: YR0066



Basic Information

Molecular Weight 115 kDa

Endotoxin <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay

Sterility 0.2 µm filtration

Aggregation <5% Determined by SECP

Purity >95% Determined by SDS-PAGE

Background

What is research grade Aflibercept biosimilar? Research grade Aflibercept biosimilar has the same amino acid sequence as Aflibercept (trade name Eylea), a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). It inhibits vascular endothelial growth factor (VEGF), and is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Aflibercept is a dimeric glycoprotein with a molecular weight of 96.9 kilo Daltons (kDa). Glycosylation adds its molecular weight to 115 kDa in total. Ziv-aflibercept (trade name Zaltrap) was developed as an injection for treatment of metastatic colorectal cancer.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical P K and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone Aflibercept Biosimilar **Isotype** Human IgG1 Fc

Immunogen

/

RecommendedIsotype Control(s) In Vivo Grade Recombinant Human IgG1 Fc Protein

Recommended Dilution Buffer

1×PBS pH 6.1

Contact

6	400-999-6126
\times	cn.market@abclonal.com.cn
€	www.abclonal.com.cn

Product Information

Production Purified from cell culture supernatant in an animal-free facility **Purification** Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)